NIFTY 50

Sun Pharma Q2 profit at Rs 1,065 crore: Here's what brokerages are recommending on the stock

Updated : November 09, 2019 06:15 AM IST

Drug major Sun Pharmaceutical Industries on Thursday reported a consolidated net profit of Rs 1,065 crore for the second quarter ended September 2019. In the corresponding quarter last year, the company posted a net loss of Rs 218.82 crore.

Total revenue from operations during the period under review stood at Rs 8,123.35 crore as against Rs 6,937.63 crore in the year-ago quarter, it said.

Brokerages are positive on the stock. Here's what they say:

  • CLSA has a 'buy' call on the stock with the target price unchanged at Rs 540. India sales offset, weak US sales, strong execution on ramp-up of specialty pipeline in the second half can drive the rerating, it said.

  • Jefferies maintains its 'buy' call on the stock. It remains positive on the outlook for the specialty business.

  • Credit Suisse maintains its 'neutral' call with a target of Rs 450. The street would want to watch the ramp-up of the specialty drug pipeline and maybe that seems to be weighing a bit on the sentiment, it said.
primo org
Have you signed up for Primo, our daily newsletter?
It has all the stories and data on the market, business, economy and tech that you need to know.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV